
Novo Nordisk slumps as it cuts sales forecast, names new CEO
Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

MSD trims outlook as it aims to shave $3bn off costs
MSD is embarking on a $3bn cost-reduction drive to prepare for the loss of patent protection for cancer blockbuster Keytruda.

FDA gives the go-ahead to restart Elevidys shipments
Sarepta has restarted distribution of its Duchenne muscular dystrophy gene therapy Elevidys, but only for patients who can walk.

Pharma tariffs set to arrive with US-EU trade deal
After some initial confusion, it has been confirmed that the 15% tariff rate on US imports from the EU will extend to pharmaceuticals.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content

Revolutionising Clinical Trials: Evolution Summit 2025 Retur...
Marcus Evans is proud to announce the Evolution Summit September 2025, an exclusive, invitation-only event bringing together leading clinical trial executives, innovative suppliers

Welcome to the 3rd Spatial Biology for Drug Development Summ...
Transforming Research & Development with Faster, More Precise Spatial Insights

2nd Hit ID Summit
Why prioritise your hit discovery game? Finding the right chemical start points is crucial to help you save time and costs in the long run.

Unlocking the Potential of Targeting the Innate Immune Syste...
Ready to Catalyze the Next Wave of Inflammasome Therapies?

The Inaugural Market Access for CNS Therapeutics Summit Has ...
The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...